Neurosense Therapeutics’ PrimeC significantly reduces blood levels of miRNAs linked to amyotrophic lateral sclerosis, trial data showed.

Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

The ALS Association and workplace learning company Schoox are partnering to offer education resources to providers, ...

A rare mutation that leads to high CREB3 activity is associated with a reduced risk of developing ALS and slower disease ...

TRE-515, a small molecule inhibitor of deoxycytidine kinase, is being developed for autoimmune diseases and in clinical ...

Verge Genomics will use digital biomarkers to assess short-term disease progression in an ALS trial testing its VRG50635 ...

Edaravone may exert its neuroprotective effects in ALS by also correcting the abnormal localization of TDP-43, a key ...

Trace is partnering with Unlearn as it advances plans for a clinical trial of its treatment candidate that targets the UNC13A ...

Columnist Kristin Neva says a couple days in the Florida sunshine, away from the demands of caregiving, did wonders for her ...

Improvement may seem unlikely for people with ALS, but columnist Dagmar Munn shares how she's learned to set health goals — ...

The U.S. Food and Drug Administration approved treatment for 11 patients with the rare familial ALS caused by mutations in ...